Friday, June 17, 2016

University of Iowa retinal specialists are leading the first randomized, controlled phase III gene therapy trial involving patients with RPE65 mutation-associated inherited retinal dystrophies.

The study is investigating treatment with adeno-associated viral vector delivery of human RPE65 in patients and is showing favorable results for improved vision.  It is being conducted at the University of Iowa and Children’s Hospital of Philadelphia. More details about the study and findings thus far are at:

Story Source: UI Health Care Marketing and Communications, 200 Hawkins Drive, Room W319 GH, Iowa City, Iowa 52242-1009